Related Experiment Video
Updated: Nov 16, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
New strategies to develop new medications for lung cancer and metastasis
1Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
Abstract:
With the advances in cancer and molecular biology and the rapid progress in genomics, significant progress has been made in the treatment of lung cancer in the past decade. Targeted therapies have been developed for nonsmall cell lung cancer (NSCLC), and significant improvement in survival has been achieved. There is still, however, no cure for advanced NSCLC. Resistance to initial therapy is universal, and the lethal outcome of metastatic disease still remains. Approaches to preventing metastases and overcoming resistance to therapy are necessary to ensure long-term survival of patients with advanced lung cancer.
Insights
Targeted therapies have improved survival for nonsmall cell lung cancer (NSCLC), but a cure for advanced NSCLC remains elusive. New strategies are needed to prevent metastasis and overcome treatment resistance for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Significant advancements in cancer treatment over the last decade, driven by molecular biology and genomics.
- Development of targeted therapies for nonsmall cell lung cancer (NSCLC) has led to improved survival rates.
Purpose of the Study:
- To address the unmet need for a cure in advanced nonsmall cell lung cancer (NSCLC).
- To explore novel approaches for preventing cancer metastasis and overcoming therapeutic resistance.
Main Methods:
- Review of recent progress in lung cancer treatment.
- Analysis of targeted therapy efficacy and limitations in NSCLC.
Main Results:
- Targeted therapies have shown significant improvements in survival for NSCLC patients.
- Universal resistance to initial therapies and the lethal nature of metastatic disease persist.
Conclusions:
- Despite progress, advanced NSCLC remains incurable.
- Preventing metastasis and overcoming therapy resistance are crucial for achieving long-term survival in advanced NSCLC patients.
More Related Videos
07:44Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation